Roots Analysis’ Post

𝐏𝐡𝐚𝐫𝐦𝐚 𝐆𝐢𝐚𝐧𝐭𝐬 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲: Is this becoming a trend? Yesterday, 𝐁𝐌𝐒 𝐢𝐧𝐯𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐀𝐛𝐚𝐭𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, to advance Treg Cell Therapies with Abata’s lead program, ABA-101, set to enter clinical trials for progressive MS, presenting a potential breakthrough opportunity. Interestingly, BMS' investment in Abata is just one of several major equity investments by large pharma in cell therapy biotech firms this year. 𝘏𝘦𝘳𝘦 𝘢𝘳𝘦 𝘴𝘰𝘮𝘦 𝘰𝘵𝘩𝘦𝘳 𝘯𝘰𝘵𝘢𝘣𝘭𝘦 𝘦𝘹𝘢𝘮𝘱𝘭𝘦𝘴.. ➡️ AstraZeneca made a major investment in Cellectis, securing access to cutting-edge gene editing technologies. This strategic move enables AZ to expand its pipeline with up to 10 new products aimed at oncology, immunology, and rare diseases, addressing critical unmet medical needs. 𝐓𝐡𝐞 𝐚𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞𝐝 𝐚 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐞𝐪𝐮𝐢𝐭𝐲 𝐬𝐭𝐚𝐤𝐞 of around 44%, and it provides AstraZeneca with substantial influence over the collaboration’s direction, along with options to license future products. Strategic control. 👉 BioNTech also went big with a $200 million investment in Autolus Therapeutics to enhance its CAR-T cell therapy pipeline. The collaboration allows BioNTech to advance its BNT211 program and utilise Autolus’ manufacturing capabilities, expediting market entry for therapies targeting CLDN6+ tumours. The deal included co-commercialisation rights and revenue sharing, providing BioNTech with financial benefits and shared risks, while strengthening its competitive position in the CAR-T market. A nice win-win. ✅ These 3 investments highlight a decisive strategy by large pharma to accelerate and diversify their pipeline advancements and position themselves early at the cutting edge of transformative CGTs and emerging tech while managing risks and maximizing returns. 𝐖𝐡𝐨 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐛𝐢𝐠 𝐭𝐚𝐫𝐠𝐞𝐭 𝐟𝐨𝐫 𝐚 𝐥𝐚𝐫𝐠𝐞 𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭? #celltherapy #oncology #biotech #CGTweekly

🌟 Discover the Swiss Biotech Revolution! Switzerland isn't just about chocolates and stunning landscapes—it's a powerhouse of biotech innovation! 🚀 From groundbreaking cancer treatments to regenerative medicine, Swiss startups are leading the charge. Dive into this latest article featuring 18 Swiss biotech companies that are transforming the future of healthcare. 🌍💉 #rare #raredisease #rarediseases #healthcare #biotech #pharma #pharmaceuticals #Switzerland #lifescience

OncoDxRx’s PGA Enables Data-Driven Clinical Decision-Making for Non-Responders OncoDxRx’s pride, the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) technology, has showcased its capability in drug response prediction using in vitro patient testing and in silico data analytics. Developed to gap-fill the limitation of biomarker testing to benefit more patients for precision therapy, this unprecedented technology could significantly expand treatment options for those patient non-responders. In terms of its characteristics, PGA boasts high precision, throughput and efficiency, making it a reliable test to inform clinical decision. It is included with novel mRNA biomarkers, including cancer type-specific and patient-derived gene expression signature, to ensure real-time and precise prediction of drug efficacy for each individual patient. Its design also ensures resilience in clinical settings. Using digital data analytics, the PGA assay streamlines workflow, enabling greatest predictive power while maintaining quick turnaround. The PGA technology is versatile and highly personalized as it can be employed for various cancer types and different patients, making it useful for treatment selection especially when standard of care is exhausted. With a seamless sample-to-result process, the PGA test can deliver a customized report within 5 days. The recent launch of PGA marks a significant milestone for OncoDxRx, as the technology now join the biomarker testing (or companion diagnostics) as capable platforms required for precision therapy. Similar to other proprietary technologies, PGA is used exclusively within the company, with partner labs and therefore competition is restrictive, yet there is no equivalent or nothing close on the marker today. The PGA launch ensures OncoDxRx’s leading cell-free mRNA capability, expertise and knowhow. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

**Belgium's Biotech Boom: A Hub of Innovation!** #Belgium is emerging as a European leader in biotechnology, with pioneering companies like Galapagos, argenx, and UCB making significant strides in gene therapy, cancer treatments, and rare diseases. The country's favorable innovation environment attracts investments and talent, reinforcing its global biotech position. Discover how these companies are driving the industry's growth and shaping the future of healthcare. #Biotech #Innovation #Belgium #Healthcare #Technology #Investment Read more Labiotech.eu :

𝐓𝐡𝐫𝐞𝐞 𝐂𝐆𝐓 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐌𝐚𝐤𝐞 𝐇𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐬: Milestone Achievements This Week 👇 In a challenging funding landscape, it’s inspiring to see small biotech companies demonstrating resilience through milestone-based partnerships. 𝘏𝘦𝘳𝘦'𝘴 𝘵𝘩𝘳𝘦𝘦 𝘣𝘪𝘰𝘵𝘦𝘤𝘩𝘴 𝘢𝘤𝘩𝘪𝘦𝘷𝘪𝘯𝘨 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦𝘴 𝘢𝘭𝘭 𝘪𝘯 𝘵𝘩𝘦 𝘴𝘢𝘮𝘦 𝘸𝘦𝘦𝘬: 1. Precision BioSciences received $13M from Imugene, including $9.75M cash, to support its gene-editing platform and its oncology program, azercabtagene zapreleucel (azer-cel). 2. Sonoma Biotherapeutics earned $45M from Regeneron for progress in developing Treg cell therapies to treat autoimmune diseases. 3. Voyager Therapeutics secured $15M upfront from Novartis, with up to $305M in potential milestones, for licensing its TRACER™ capsid technology used in gene therapy. 𝐖𝐡𝐲 𝐓𝐡𝐢𝐬 𝐌𝐚𝐭𝐭𝐞𝐫𝐬: 👉 These milestones are crucial for accelerating the development of innovation in CGT, it also secures immediate funding for small biotech companies, such as Precision BioSciences and Sonoma Biotherapeutics. Ultimately, it's a great reinforcement of industry confidence by validating the science and effectiveness of treatments and strengthening partnerships with major pharmaceutical leaders such as Regeneron and Novartis. What are your thoughts - do you see this as a strong indicator of progress? #celltherapy #genetherapy #cellandgenetherapy #CGTweekly

OncoDxRx Boosting Precision Oncology Pipelines with Disruptive PGA Technology Announced by the liquid biopsy company OncoDxRx, the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) launch follows a series of live tests and demonstrations to evaluate the technology’s ability to augment existing NGS-based biomarker testing and to benefit non-responder patients in precision therapy.   Apart from the technology itself, the company has validated a complete testing procedures, which includes sample processing, cell-free RNA enrichment, gene expression profiling, and a panel of biomarkers to obtain patient-specific signatures, and associated in silico computation analyses.   According to OncoDxRx, the PGA gene-to-drug assay boasts three times more patient coverage and a 60-percent reduction in cost and turnaround over current standard of care biomarker testing. It can simultaneously screen and identify a wide variety of cancer drugs, including FDA-approved and those in clinical trials. Additionally, it has a high throughput capability, providing high-volume clinical laboratories with optimum testing power.   The PGA also features advanced gene-drug mapping annotation tools to aid in classification of drug efficacy by IC50 values and hence providing high quality of actionable data for those patients with "negative" biomarker testing results. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

🔬 Exciting News: Biohippo's Strategic Collaboration with LipExoGen! 🔬 We are thrilled to announce a groundbreaking collaboration between Biohippo and #LipExoGen, a pivotal move that underscores our commitment to advancing scientific research and development. Together, we are set to empower the scientific community with cutting-edge solutions in drug development, immunology, oncology, and more. 🌐 About Our Partner, LipExoGen: LipExoGen is a leading biotechnology company specializing in a diverse range of products and services, with a primary focus on #liposome, #exosome, and gene-related applications. Their offerings include #Lentiviral Particles, #Liposomal Particles, Lipid Nanoparticles (LNPs), Exosomes, and #Plasmids, catering to various research needs. 🔗 Direct Contact for Product Inquiries: As we update our website with these innovative products, we invite you to reach out directly for any questions or interest. Your involvement is vital to us, and we are committed to providing comprehensive information and support. 💡 Stay tuned for more updates and explore the possibilities of this collaboration! 📩 Get in Touch with Biohippo: For more details about our collaboration, products, and how we can assist you with your research, please feel free to contact us https://lnkd.in/ezESsU4C #Biohippo #LipExoGen #Collaboration #Biotechnology #scientificresearch #ResearchandDevelopment #InnovationInScience #ScientificPartnership

Valerio Therapeutics S.A., a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics, announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie, one of France’s leading cancer centers. Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell engagers, blocking and binding sdAbs, or CAR-T sdAb drug candidates for multiple therapeutic areas. Emglev’s proprietary synthetic sdAb libraries overcome the current barriers of conventional antibody discovery by providing unique targets and selecting humanized or fully human sdAbs entirely in vitro. These sdAbs are validated for a wide array of therapeutic applications, offering a distinct advantage in antibody development. Shefali Agarwal, Christelle Masdeu, Sandrine Moutel, Cécile Campagne Read more - https://lnkd.in/gTXrQcJX To share your startup story write us on - contact@startuprise.co.uk #valerio #Emglev #acqusisition #Biotech #news #startup

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Nvidia's biotech moment; Regeneron launches venture arm; New GLP-1 player enters; Sanofi rejigs cancer pact, vaccine ops; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Next month, we will be partnering with the Financial Times on its US Pharma and Biotech Summit returns to New York. There are options for both in-person and virtual attendance — you can find the speakers and agenda here. Nvidia’s biotech moment Over the last decade, multiple tech giants have tried and failed to get into healthcare. Nvidia, though, appears to be the exception. Is this finally tech’s healthcare moment? Andrew Dunn takes a deep dive into the chipmaker’s plan to dominate biotech’s AI revolution. Regeneron launches venture arm Regeneron is getting into venture investing. The storied drugmaker will commit $100 million per year for five years to Regeneron Ventures, which will invest in biotech startups, devices, tools and “enabling technologies.” The fund will be led by former Regeneron execs. New GLP-1 player enters ARCH-backed startup Metsera officially launched with $290 million to challenge Novo Nordisk and Eli Lilly’s duopoly atop today’s market for obesity drugs. Its lead asset is a GLP-1 agonist now in the clinic in the US, and it plans to test combinations of various drugs, but the rest of the clinical strategy remains closely guarded. Sanofi rejigs cancer pact, vaccine ops Sanofi isn’t done reorganizing its businesses. In addition to trimming its $6.15 billion biobuck pact with California biotech IGM — removing the three targets they had planned in oncology and thus taking $3 billion off the table — it is also overhauling its US commercial operations for its vaccines and will cut an undisclosed number of jobs. WHAT WE’RE WATCHING NEXT WEEK Multiple pharma companies are set to report their Q1 earnings, including Sanofi, Roche, Novartis, AstraZeneca, GSK and more. R&D * Eli Lilly’s weight loss drug Zepbound hit the primary endpoints in two Phase 3 trials for adults with obstructive sleep apnea and obesity, setting the stage for the first potential approval of a drug for the breathing disorder. The company is planning a filing in mid-2024. * Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal * Sage nixes program for Parkinson’s disease after Phase 2 failure * Cerevel notches Phase 3 Parkinson’s win ahead of AbbVie transaction closing * FDA hits Neumora with clinical hold for schizophrenia drug after preclinical data showed convulsions in rabbits * Novartis showcases Ph3 data… #lucidquest #genetherapy #celltherapy